Drug helps women who stop smoking keep weight off
2012-12-11
(Press-News.org) A medication being tested to help smokers kick the habit also may help avoid the weight gain that is common after quitting but only in women, according to a study published in the December issue of Biological Psychiatry. This is the first medication shown to reduce weight gain for up to one year in women smokers who quit.
Naltrexone — an opioid blocker that can dampen the desire for alcohol, heroin and nicotine, as well as the pleasures of eating — helped men quit smoking. It improved their quit rates after three months of treatment in a large controlled trial, from 17 percent for those who did not get the drug up to 30 percent for those who did.
The drug did not improve quit rates for women beyond that of the placebo. But for the women who successfully quit smoking, their weight gain was reduced by more than half. After three months, those who took naltrexone gained an average of 2.3 pounds while those who took a placebo gained 5.1 pounds.
"When trying to stop smoking, women tend to gain more weight than men and to be more concerned about gaining that weight," said study author Andrea King, PhD, professor of psychiatry and behavioral neuroscience at the University of Chicago Medicine. "Women who try to quit may be so worried about putting on weight in the process that they soon give up, and this is less commonly found in men. Adding naltrexone to standard treatment might help women get through that difficult early period."
While tobacco use is the leading cause of preventable death in the United States, obesity is the second leading cause. Ironically, more than 80 percent of those who are able to stop smoking put on at least five pounds in the year after quitting. Up to 25 percent of those who quit gain more than 15 pounds.
For this study, researchers combined data from the two largest trials using naltrexone to help volunteers stop smoking. The trial included 700 participants, 315 from the University of Chicago and 385 from Yale University. For six to 12 weeks after their quit date, participants took either naltrexone or a placebo. They also used a nicotine patch and attended smoking-cessation counseling for the first month.
After six months, 159 of the 700 participants (23 percent), including 77 women, remained verifiably smoke-free. After 12 months, that number fell to 115 (16 percent), including 57 women.
Over the first 12 months after quitting, weight gain continued to increase for successful quitters, but the benefits of the early treatment with naltrexone persisted. The effect was diminished, however. From a 50-percent reduction in weight gain for those taking the drug when measured at three months, the difference decreased to 40 percent (7.3 vs. 12.1 pounds) at six months, and to 20 percent (13 vs. 16.3 pounds) at 12 months.
"Naltrexone has produced the most promising results to date for helping women who quit smoking gain less weight," King said. "It is possible that the opioid blocker reduces women's tendency to eat high fat and sweet foods when they quit smoking."
But the available tools to help people stop smoking "are not satisfactory," King added. Smoking remains "a huge health problem and most adults in the United States are either overweight or obese. Our study demonstrates that naltrexone may be a promising medication to treat tobacco dependence and unlike the other approved medications, appears to help reduce weight gain for many."
INFORMATION:
Additional authors of the study include Lingjiao Zhang of the University of Chicago, Dingcai Cao of the University of Illinois at Chicago, and Stephanie O'Malley of Yale University. The National Institutes of Health and the Robert Wood Johnson Foundation supported this research. The paper is available online at: http://dx.doi.org/10.1016/j.biopsych.2012.09.025
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-12-11
PASADENA, Calif.—A secret agent is racing against time. He knows a bomb is nearby. He rounds a corner, spots a pile of suspicious boxes in the alleyway, and pulls out his cell phone. As he scans it over the packages, their contents appear onscreen. In the nick of time, his handy smartphone application reveals an explosive device, and the agent saves the day.
Sound far-fetched? In fact it is a real possibility, thanks to tiny inexpensive silicon microchips developed by a pair of electrical engineers at the California Institute of Technology (Caltech). The chips generate ...
2012-12-11
ATLANTA – Auditory systems differ between sexes in sparrows depending on the season, a Georgia State University neuroscientist has found. The work adds to our knowledge of how the parts of the nervous system, including that of humans, are able to change.
Megan Gall, a post-doctoral researcher with Georgia State's Neuroscience Institute, tested the peripheral auditory systems of male and female house sparrows, comparing the hearing of each gender during non-breeding seasons and breeding seasons.
Gall measured frequency selectivity – the ability to tell sounds that are ...
2012-12-11
KINGSTON, R.I.— December 10, 2012 – A University of Rhode Island researcher has discovered that the weight-loss drug orlistat, known by the brand names Xenical and Alli, inhibits a key enzyme that may lead to "severe toxicity of internal organs such as the liver and kidney." The inhibition is irreversible and can be caused by a low level of the drug.
Professor Bingfang Yan's study funded by the National Institutes of Health, also found that the drug alters efficacy of medicines, and particularly limits the effectiveness of some anti-cancer drugs.
Part of the research ...
2012-12-11
NEW YORK (Dec. 10, 2012) -- Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL (ABC-DLBCL), remains a major therapeutic challenge. An international research team, led by two laboratories from Weill Cornell Medical College, has developed a new experimental drug therapy to target this aggressive form of lymphoma.
In the journal Cancer Cell, researchers report the discovery of an experimental small molecule ...
2012-12-11
URBANA – Every year farmers spend a lot of money trying to control corn rootworm larvae, which are a significant threat to maize production in the United States and, more recently, in Europe. University of Illinois researchers have been working on validating a model for estimating damage functions.
Nicholas Tinsley, a doctoral candidate in crop sciences, has refined a model developed in 2009 by researchers at the University of Wisconsin and in Brescia, Italy, to describe the relationship between root injury caused by these pests and yield loss. He used the equivalent ...
2012-12-11
DETROIT - Both nature and nurture appear to be significant factors in early antisocial behaviors of adopted children, a Wayne State University researcher believes.
Christopher Trentacosta, Ph.D., assistant professor of psychology in the College of Liberal Arts and Sciences, recently examined data from 361 linked triads (birth mother, adoptive parents, adopted child) in order to assess externalizing behavioral problems such as aggression and defiance when children were 18, 27 and 54 months of age.
The triads were part of the Early Growth and Development Study (EGDS), ...
2012-12-11
CHAMPAIGN, Ill. — The small kerosene lamps that light millions of homes in developing countries have a dark side: black carbon – fine particles of soot released into the atmosphere.
New measurements show that kerosene wick lamps release 20 times more black carbon than previously thought, say researchers at the University of Illinois and the University of California, Berkeley. The group published its findings in the journal Environmental Science and Technology.
Black carbon is a hazard for human health and the environment, affecting air quality both indoors and out. ...
2012-12-11
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute lymphoblastic leukemia (B-ALL), at the annual meeting of the American Society of Hematology ...
2012-12-11
Over past decades, many areas of the forested Amazon basin have become a patchwork of farms, pastures and second-growth forest as people have moved in and cleared land--but now many are moving out, in search of economic opportunities in newly booming Amazonian cities. The resulting depopulation of rural areas, along with spreading road networks and increased drought are causing more and bigger fires to ravage vast stretches, say researchers in a new study. The study, focusing on the Peruvian Amazon, is the latest to suggest that land-use changes and other factors, including ...
2012-12-11
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.
In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."
The measurements were made ...
LAST 30 PRESS RELEASES:
[Press-News.org] Drug helps women who stop smoking keep weight off
